Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
Genetic and/or epigenetic changes provide antigen-derived diversity in neoplastic cells. Beside, these cells do not initiate immune response of host organisms. A variety of factors are responsible for the resistant to treatment, including individual variations in patients and somatic cell genetic di...
Saved in:
| Main Authors: | Magdalena Witkowska, Piotr Smolewski |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2018/1982423 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Checkpoint Inhibitors in the Treatment of Lymphomas
by: KV Lepik
Published: (2018-10-01) -
Immune checkpoint inhibitors in pediatric hematologic malignancies
by: I. V. Gribkova
Published: (2023-05-01) -
Advances in radiotherapy enhancing the efficacy of immune checkpoint inhibitors in malignant
by: Yao Liao, et al.
Published: (2025-07-01) -
Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors
by: Abdulrahman Alghabban, MD, et al.
Published: (2025-05-01) -
Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma
by: Yoshito Nishimura, et al.
Published: (2025-08-01)